The project will entail 2 consecutive phases:
The first phase (M0 – M24), will be performed on an already acquired preclinical SPCCT (installed May 2015 at CERMEP) limited to small animal studies. The following activities will be performed:
- pre-clinical development of the method,
- evaluation of the relative sensitivity and specificity of SPCCT contrast agents,
- screening and tests on the newly developed specific contrast agents
- technological development in terms of detector calibration and first image post-processing steps.
The second phase (M24 - M48) will be focused on translating the first phase results on large animals and later on humans by developing and installing a new human sized clinical SPCCT and validating the contrast agents on stroke, myocardial infarction and atherosclerosis models.